Stockreport

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 European Committee for Treatment and R...

TG Therapeutics, Inc.  (TGTX) 
Last tg therapeutics, inc. earnings: 11/12 07:34 am Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
PDF NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, highlighting data from the ULTIMA [Read more]